Tumor Necrosis Factor Receptor Superfamily Member 8 / CD30 (TNFRSF8) Antibody (APC)

Este producto es parte de TNFRSF8 - TNF receptor superfamily member 8
Tumor Necrosis Factor Receptor Superfamily Member 8 / CD30 (TNFRSF8) Antibody (APC)

Pida mas información

935106861

info@markelab.com

Precio

429€ (100 tests)

Antibody anti-TNFRSF8

proveedor

Abbexa

reference

abx347287

Tested Applications

FCM

reactivity

Human

status

RUO

clonality

Monoclonal

Descripción

Tumor Necrosis Factor Receptor Superfamily Member 8 / CD30 (TNFRSF8) Antibody (APC) is a APC-conjugated Mouse Monoclonal antibody for Tumor Necrosis Factor Receptor Superfamily Member 8 / CD30 (TNFRSF8).

Características del producto

category

Primary Antibodies


clonality

Monoclonal


reactivity

Human


immunogen target

Tumor Necrosis Factor Receptor Superfamily Member 8 / CD30 (TNFRSF8)


host

Mouse


conjugation

APC


tested applications

FCM


purification

Purified by size-exclusion chromatography.


recommended dilution

FCM: 10 µl/100 µl whole blood or 106 cells. Optimal dilutions/concentrations should be determined by the end user.


buffer

PBS, pH 7.4, 15 mM sodium azide.


size 1

100 tests


storage

Store at 2-8°C in the dark. Do not freeze.


or code

TNFRSF8


dry ice

No


availability

Shipped within 5-12 working days.


Quizá le pueda interesar

Human TNFRSF8(Tumor necrosis factor receptor superfamily member 8) ELISA Kit

Human TNFRSF8(Tumor necrosis factor receptor superfamily member 8) ELISA Kit

proveedor

FineTest

reference

EH0640

reactivity

human

status

RUO

Precio a consultar

Ver más

Mouse CD30(Cluster of differentiation 30) ELISA Kit

Mouse CD30(Cluster of differentiation 30) ELISA Kit

proveedor

FineTest

reference

EM0046

reactivity

mouse

status

RUO

Precio a consultar

Ver más

Rat Tnfrsf8(Tumor necrosis factor receptor superfamily member 8) ELISA Kit

Rat Tnfrsf8(Tumor necrosis factor receptor superfamily member 8) ELISA Kit

proveedor

FineTest

reference

ER0220

reactivity

rat

status

RUO

Precio a consultar

Ver más